Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

New Products In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

Abbott’s Rx Herculink Elite

You may also be interested in...



FDA Orders Post-Market Studies On Metal-On-Metal Hips

FDA has ordered 21 current and former manufacturers of metal-on-metal total hip replacement systems to conduct post-market surveillance studies of their devices to assess metal toxicity risks.

Research In Brief

Benefits, risks higher for mesh prolapse repair

Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent

South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

NWW: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients

Getting Personal With Tom Miller: CEO Turned VC On Ethical Bets In Diagnostics

Postmarket Surveillance Continues To Challenge AI/ML Device Regulators

Q&A: Allyson Mullen On ‘Uncharted Waters’ Of Breakthrough Pathway

See All
UsernamePublicRestriction

Register

MT030439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By